ERBB2 and breast cancer: [16] showed that the 5-year OS rate of patients with BC of varying molecular subtypes was 90.3% for luminal A BC, 88.7% for luminal B BC, 79.0% for TNBC and 78.8% for HER2-positive BC, and the 5-year DFS rate was 86.8% for luminal A BC, 83.2% for luminal B BC, 73.5% for TNBC and 66.0% for HER2-positive BC.